Recent Articles

Lexicon Limbo: From “Healthspan” to “New Normal” and “Discharge”

David B. Nash, MD, MBA

May 2019 Vol 12, No 3 - Editorial

Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis

Jeffrey T. Guptill, MD, MA, MHS, M. Chris Runken, PharmD, Michael Eaddy, PharmD, PhD, Orsolya Lunacsek, PhD, Rupali M. Fuldeore, MS

May 2019 Vol 12, No 3 - Clinical, Original Research

Stakeholder Perspective

Enhanced Understanding and Management of Rare Diseases Can Reduce Costs, Improve Clinical Outcomes

by James T. Kenney, RPh, MBA

Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases

Lonnie Wen, RPh, PhD, Adriana Valderrama, PhD, Mary E. Costantino, PhD, Stacey Simmons, MD

May 2019 Vol 12, No 3 - Clinical, Original Research

Prevalence and Economic Burden of Epilepsy in the Institutionalized Medicare Fee-for-Service Population

Kathryn Fitch, RN, MEd, Xiaoyun Pan, MS, PhD, Jocelyn Lau, MPH, Tyler Engel, ASA, MAAA, Krithika Rajagopalan, MS, PhD

May 2019 Vol 12, No 3 - Business, Original Research

Most Popular Articles

Will We Ever Bend the Cost Curve in Healthcare?

Ehsan U. Syed, MD

Online First - Opinion

Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Conference Correspondent - ASCO 2019 - Chronic Lymphocytic Leukemia

Final Analysis from RESONATE: Six-Year Follow-Up in Patients with Previously Treated CLL/SLL Receiving Ibrutinib

Conference Correspondent - ASCO 2019 - Chronic Lymphocytic Leukemia

Online First

Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing

Joshua A. Roth, PhD, MHA, Theo deVos, PhD, Scott D. Ramsey, MD, PhD

Select Drug Profiles

Tavalisse (Fostamatinib Disodium Hexahydrate) First Spleen Tyrosine Kinase Inhibitor Approved for Chronic Immune Thrombocytopenia

Loretta Fala

Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy

Loretta Fala

Reader Poll

*Should the government fund healthcare cost-sharing payments to insurers to reduce the economic burden on consumers?

Yes
No

Submit

• 
• 
• 

• 
• 
• 

•